EMI (Encore Medical) Net Current Asset Value: $-0.21 (As of Dec. 2025)


What is Encore Medical Net Current Asset Value?

Encore Medical EMI Net Current Asset Value is $-0.21 as of Dec. 2025.

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Encore Medical's net current asset value per share for the quarter that ended in Dec. 2025 was $-0.21.

The historical rank and industry rank for Encore Medical's Net Current Asset Value or its related term are showing as below:

EMI's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.1
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Encore Medical  (AMEX:EMI) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Encore Medical Net Current Asset Value Related Terms


Encore Medical Net Current Asset Value Historical Data

* Premium members only.

The historical data trend for Encore Medical's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Net Current Asset Value Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Net Current Asset Value
-0.07 -0.14 -0.21

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Net Current Asset Value Get a 7-Day Free Trial 0.00 -0.14 -0.14 -0.17 -0.21

EMI vs : Net Current Asset Value Comparison

For the Medical Instruments & Supplies subindustry, Encore Medical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encore Medical Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Encore Medical's Price-to-Net-Current-Asset-Value falls into.



Encore Medical Net Current Asset Value Calculation

Encore Medical's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2025 is calculated as

Net Current Asset Value Per Share(A: Dec. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.802-3.83-0-0.009)/9.743
=-0.21

Encore Medical's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2025 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.802-3.83-0-0.009)/9.743
=-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Current Asset Value of $-0.21 mean?
Encore Medical (EMI) has a Net Current Asset Value of $-0.21 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Encore Medical and its competitors.
Is Encore Medical's Net Current Asset Value too high?
Encore Medical's current Net Current Asset Value is $-0.21.
How does Encore Medical's Net Current Asset Value compare to ?
Encore Medical's Net Current Asset Value of $-0.21 can be compared against companies in the Medical Devices & Instruments industry. The industry median Net Current Asset Value is 5.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.10, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Encore Medical and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encore Medical's current Net Current Asset Value is $-0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Net Current Asset Value of $-0.21. The current Net Current Asset Value is $-0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Encore Medical (EMI), the current Net Current Asset Value is $-0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).